This work is licensed under the Creative Commons Attribution 4.0 International License.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111–188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. PMID: 31504418.MachFBaigentCCatapanoALKoskinasKCCasulaMBadimonLChapmanMJDe BackerGGDelgadoVFerenceBAGrahamIMHallidayALandmesserUMihaylovaBPedersenTRRiccardiGRichterDJSabatineMSTaskinenMRTokgozogluLWiklundOESC Scientific Document Group2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEur Heart J2020Jan141111118810.1093/eurheartj/ehz455Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. PMID: 31504418.31504418Open DOISearch in Google Scholar
Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014;66(2):124–132. doi:10.3138/ptc.2012-65MendesPRoblesPGMathurSStatin-induced rhabdomyolysis: a comprehensive review of case reportsPhysiother Can.201466212413210.3138/ptc.2012-65400640424799748Open DOISearch in Google Scholar
Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxf Med Case Reports. 2018;2018(3):omx104. Published 2018 Mar 14. doi:10.1093/omcr/omx104EzadSCheemaHCollinsNStatin-induced rhabdomyolysis: a complication of a commonly overlooked drug interactionOxf Med Case Reports201820183omx104. Published 2018 Mar 14.10.1093/omcr/omx104585300129593874Open DOISearch in Google Scholar
Mohamed MFH, Salameh OK, Saeed AAM. Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death. Am J Case Rep. 2019 May 18;20:709–712. doi: 10.12659/AJCR.914707. PMID: 31101801; PMCID: PMC6537756.MohamedMFHSalamehOKSaeedAAMStatin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to DeathAm J Case Rep.2019May182070971210.12659/AJCR.914707PMID: 31101801; PMCID: PMC6537756.653775631101801Open DOISearch in Google Scholar
Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019 Jan 18;124(2):328–350. doi: 10.1161/CIRCRESAHA.118.312782. PMID: 30653440.WardNCWattsGFEckelRHStatin ToxicityCirc Res.2019Jan18124232835010.1161/CIRCRESAHA.118.312782PMID: 30653440.30653440Open DOISearch in Google Scholar
Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019 Mar;16(3):155–165. doi: 10.1038/s41569-018-0107-8. PMID: 30420622.SabatineMSPCSK9 inhibitors: clinical evidence and implementationNat Rev Cardiol.2019Mar16315516510.1038/s41569-018-0107-8PMID: 30420622.30420622Open DOISearch in Google Scholar
Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016 Jul–Aug;10(4):739–747. doi: 10.1016/j.jacl.2016.05.002. Epub 2016 May 13. PMID: 27578103.TobertJANewmanCBThe nocebo effect in the context of statin intoleranceJ Clin Lipidol.2016Jul–Aug10473974710.1016/j.jacl.2016.05.002Epub 2016 May 13. PMID: 27578103.27578103Open DOISearch in Google Scholar
Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016 Feb 18;374(7):664–9. doi: 10.1056/NEJMra1515161. PMID: 26886523.MammenALStatin-Associated Autoimmune MyopathyN Engl J Med.2016Feb183747664910.1056/NEJMra1515161PMID: 26886523.26886523Open DOISearch in Google Scholar
Gallo A, Perregaux J, Bruckert E. Advances in the management of statin myopathy. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):142–151. doi: 10.1097/MED.0000000000000595. PMID: 33278129GalloAPerregauxJBruckertEAdvances in the management of statin myopathyCurr Opin Endocrinol Diabetes Obes.2021Apr128214215110.1097/MED.0000000000000595PMID: 3327812933278129Open DOISearch in Google Scholar